Literature DB >> 1069548

Randomized trial of Bacillus Calmette-Guérin (percutaneous administration) as surgical adjuvant immunotherapy for patients with stage-II melanoma.

C M Pinsky, Y Hirshaut, H J Wanebo, J G Fortner, V Miké, D Schottenfeld, H F Oettgen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 1069548     DOI： 10.1111/j.1749-6632.1976.tb41697.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  6 in total

1.  Immunotherapy and chemoimmunotherapy of malignant disease with BCG and nonviable mycobacterial fractions.

Authors:  M A Schwarz; J U Gutterman; E M Hersh; S P Richman; G M Mavligit
Journal:  World J Surg       Date:  1977-09       Impact factor: 3.352

Review 2.  Combined modality therapy of malignant melanoma.

Authors:  E M Hersh; J U Gutterman; C M McBride
Journal:  World J Surg       Date:  1979-07-30       Impact factor: 3.352

3.  Recurrent malignant melanoma: effect of adjuvant immunotherapy on survival.

Authors:  P B McCulloch; P B Dent; M Blajchman; W M Muirhead; R A Price
Journal:  Can Med Assoc J       Date:  1977-07-09       Impact factor: 8.262

Review 4.  Immunotoxin therapy of malignant melanoma.

Authors:  L E Spitler
Journal:  Med Oncol Tumor Pharmacother       Date:  1986

5.  Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.

Authors:  Erika Vacchelli; Lorenzo Galluzzi; Alexander Eggermont; Wolf Hervé Fridman; Jerome Galon; Catherine Sautès-Fridman; Eric Tartour; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2012-09-01       Impact factor: 8.110

6.  Specific active immunotherapy does not prolong survival in surgically treated patients with stage IIB malignant melanoma and may promote early recurrence.

Authors:  D W Hedley; T J McElwain; G A Currie
Journal:  Br J Cancer       Date:  1978-04       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.